These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31761379)

  • 1. Hematopoietic stem cell gene therapy: The optimal use of lentivirus and gene editing approaches.
    Lamsfus-Calle A; Daniel-Moreno A; Ureña-Bailén G; Raju J; Antony JS; Handgretinger R; Mezger M
    Blood Rev; 2020 Mar; 40():100641. PubMed ID: 31761379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined lentiviral- and RNA-mediated CRISPR/Cas9 delivery for efficient and traceable gene editing in human hematopoietic stem and progenitor cells.
    Yudovich D; Bäckström A; Schmiderer L; Žemaitis K; Subramaniam A; Larsson J
    Sci Rep; 2020 Dec; 10(1):22393. PubMed ID: 33372184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Editing of Human Hematopoietic Stem and Progenitor Cells: Promise and Potential Hurdles.
    Yu KR; Natanson H; Dunbar CE
    Hum Gene Ther; 2016 Oct; 27(10):729-740. PubMed ID: 27483988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient transduction of hematopoietic stem cells and its potential for gene correction of hematopoietic diseases.
    Thomas D; Mostoslavsky G
    Methods Mol Biol; 2014; 1114():441-50. PubMed ID: 24557921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9 genome engineering in hematopoietic cells.
    Sürün D; von Melchner H; Schnütgen F
    Drug Discov Today Technol; 2018 Aug; 28():33-39. PubMed ID: 30205879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemistry, manufacturing and controls for gene modified hematopoietic stem cells.
    Soni S; Kohn DB
    Cytotherapy; 2019 Mar; 21(3):358-366. PubMed ID: 30745225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stem Cell Genetic Therapy for Fanconi Anemia - A New Hope.
    Hanenberg H; Roellecke K; Wiek C
    Curr Gene Ther; 2017; 16(5):309-320. PubMed ID: 28067166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic stem cell gene editing and expansion: State-of-the-art technologies and recent applications.
    Haltalli MLR; Wilkinson AC; Rodriguez-Fraticelli A; Porteus M
    Exp Hematol; 2022 Mar; 107():9-13. PubMed ID: 34973360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene editing and its application for hematological diseases.
    Osborn MJ; Belanto JJ; Tolar J; Voytas DF
    Int J Hematol; 2016 Jul; 104(1):18-28. PubMed ID: 27233509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Editing in Hematopoietic Stem Cells.
    Liao J; Wu Y
    Adv Exp Med Biol; 2023; 1442():177-199. PubMed ID: 38228965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene Therapy and Genome Editing.
    Boulad F; Mansilla-Soto J; Cabriolu A; Rivière I; Sadelain M
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):329-342. PubMed ID: 29458735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic-Stem-Cell-Targeted Gene-Addition and Gene-Editing Strategies for β-hemoglobinopathies.
    Drysdale CM; Nassehi T; Gamer J; Yapundich M; Tisdale JF; Uchida N
    Cell Stem Cell; 2021 Feb; 28(2):191-208. PubMed ID: 33545079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pluripotent stem cell based gene therapy for hematological diseases.
    Vanhee S; Vandekerckhove B
    Crit Rev Oncol Hematol; 2016 Jan; 97():238-46. PubMed ID: 26381313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Base Editors-Mediated Gene Therapy in Hematopoietic Stem Cells for Hematologic Diseases.
    Zhang C; Xu J; Wu Y; Xu C; Xu P
    Stem Cell Rev Rep; 2024 Aug; 20(6):1387-1405. PubMed ID: 38644403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of CRISPR/Cas9 gene edited hematopoietic stem cells following transplantation: A systematic review and meta-analysis of preclinical studies.
    Maganti HB; Bailey AJM; Kirkham AM; Shorr R; Pineault N; Allan DS
    Stem Cells Transl Med; 2021 Jul; 10(7):996-1007. PubMed ID: 33666363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
    Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
    Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating Immunodeficiency through HSC Gene Therapy.
    Booth C; Gaspar HB; Thrasher AJ
    Trends Mol Med; 2016 Apr; 22(4):317-327. PubMed ID: 26993219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global Transcriptional Response to CRISPR/Cas9-AAV6-Based Genome Editing in CD34
    Cromer MK; Vaidyanathan S; Ryan DE; Curry B; Lucas AB; Camarena J; Kaushik M; Hay SR; Martin RM; Steinfeld I; Bak RO; Dever DP; Hendel A; Bruhn L; Porteus MH
    Mol Ther; 2018 Oct; 26(10):2431-2442. PubMed ID: 30005866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-Cas9 technology and its application in haematological disorders.
    Zhang H; McCarty N
    Br J Haematol; 2016 Oct; 175(2):208-225. PubMed ID: 27619566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates.
    Romero Z; Lomova A; Said S; Miggelbrink A; Kuo CY; Campo-Fernandez B; Hoban MD; Masiuk KE; Clark DN; Long J; Sanchez JM; Velez M; Miyahira E; Zhang R; Brown D; Wang X; Kurmangaliyev YZ; Hollis RP; Kohn DB
    Mol Ther; 2019 Aug; 27(8):1389-1406. PubMed ID: 31178391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.